Kalaris Therapeutics Reverse Merges with AlloVir to Advance Therapies Focusing on Retinal Diseases
Shots:
- Allovir will acquire 100% outstanding shares of Kalaris, forming a combined entity that will trade as Kalaris on Nasdaq under the ticker, ‘KLRS’, with its focus on developing therapies targeting retinal diseases. Deal is anticipated to conclude in Q1’25
- On completion, the pre-Merger AlloVir stockholders will own ~25.05% & pre-Merger Kalaris stockholders will own ~74.95% of the combined entity. The merged entity expects to have $100M in cash to cover expenses & capital needs until Q4’26
- The entity will advance TH103 for which the recruitment in P-I study to assess safety, PK/PD, MTD & preliminary anti-VEGF effects on fluid and visual acuity in treatment-naïve nAMD patients has begun by Kalaris, with initial readout planned in Q3’25
Ref: AlloVir | Image: Kalaris
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
